Clinical Trial Update: Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating autologous dendritic cell vaccine therapy in patients with relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Autologous dendritic cell vaccine (dendritic cell vaccine)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: UNKNOWN